tagraxofusp

FDA Drug Profile — Elzonris

Drug Details

Generic Name
tagraxofusp
Brand Names
Elzonris
Application Number
BLA761116
Sponsor
Stemline Therapeutics, Inc.
NDC Codes
1
Dosage Forms
INJECTION, SOLUTION
Routes
INTRAVENOUS
Active Ingredients
TAGRAXOFUSP

Indications and Usage

1 INDICATIONS AND USAGE ELZONRIS is indicated for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older. ELZONRIS is a CD123-directed cytotoxin indicated for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older ( 1 )